Masimo Settles Class Action Lawsuit for $33.75 Million Amid Legal Challenges and Innovation Focus

## Masimo Corporation Faces $33.75 Million Class Action Settlement

Masimo Corporation navigates a significant legal development as a class action lawsuit filed against the company and its executives leads to a proposed settlement of $33.75 million for affected investors. This lawsuit involves shareholders who purchased Masimo's publicly traded common stock between May 4, 2022, and August 8, 2023. The United States District Court for the Southern District of California has appointed lead plaintiffs to represent the settlement class, which includes investors who allege they incurred financial damages related to the company during the specified period. While the proposed settlement aims to compensate shareholders, Masimo and its executives, including Joseph Kiani, Micah Young, Bilal Muhsin, and Eli Kammerman, deny any wrongdoing or liability.

As the court prepares to assess the proposed settlement, a hearing is scheduled for May 5, 2026, at 9:30 a.m. Pacific Time. This hearing will be pivotal, as it will address the fairness and adequacy of the settlement, certify the settlement class and representatives, and approve an allocation plan for distributing the net settlement fund among eligible class members. While the defendants maintain their position of non-liability, the proposed compensation may have far-reaching implications for both shareholder trust and the company’s public perception. Investors who consider themselves part of the settlement class are urged to stay informed, as their rights could be directly impacted.

Affected investors who have not yet received a notice about the settlement are encouraged to seek further information. Legal representatives for the plaintiffs are also seeking fees and expenses related to the class action lawsuit, which underscores the complexity and financial stakes involved. Importantly, class members are reminded that attendance at the upcoming court hearing is not mandatory to qualify for compensation from the settlement. Instead, they are advised to remain updated, as the court may notify them of any changes in hearing arrangements or other relevant developments.

In addition to its ongoing legal challenges, Masimo is recognized for its innovative medical technology products that significantly impact patient monitoring and health outcomes. The company continues to prioritize advancements in non-invasive monitoring technology, aiming to solidify its position within the healthcare industry despite the current legal landscape. This dual focus on innovation and navigating legal complexities will be crucial for Masimo as it moves forward.